Novogene provides genomic services and solutions with expertise in next-generation sequencing (NGS) and bioinformatics. Led by CEO Dr. Ruiqiang Li, the company offers commercial sequencing services and related bioinformatics analysis. It employs approximately 1,300 people and operates multiple locations around the world. Novogene holds 43 NGS-related patents and has more than 200 publications in journals such as Nature and Science. The company plans to expand in the global NGS service market and to grow its clinical sequencing R&D and services. It intends to use new funding to further strengthen its leadership position in the NGS industry.

Total raised

$75M

Funding rounds

1

Latest round

Series B

Latest activity

Nov 2016